Anticorps Recombinant de lapin anti-BCMA/TNFRSF17

BCMA/TNFRSF17 Recombinant Antibody for FC

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain

Applications

FC

Conjugaison

CoraLite®594 Fluorescent Dye

CloneNo.

241731A11

N° de cat : CL594-98215

Synonymes

TNFRSF17, 241731A11, B-cell maturation protein, BCM, BCMA



Applications testées

Résultats positifs en cytométrieU266 cells,

Dilution recommandée

ApplicationDilution
This reagent has been pre-titrated and tested for flow cytometric analysis. The suggested use of this reagent is 5 ul per 10^6 cells in a 100 µl suspension or 5 ul per 100 µl of whole blood.
Sample-dependent, check data in validation data gallery

Informations sur le produit

CL594-98215 cible BCMA/TNFRSF17 dans les applications de FC et montre une réactivité avec des échantillons Humain

Réactivité Humain
Hôte / Isotype Lapin / IgG
Clonalité Recombinant
Type Anticorps
Immunogène BCMA/TNFRSF17 Protéine recombinante Eg1812
Nom complet tumor necrosis factor receptor superfamily, member 17
Masse moléculaire calculée 184 aa, 20 kDa
Numéro d’acquisition GenBankBC058291
Symbole du gène TNFRSF17
Identification du gène (NCBI) 608
Conjugaison CoraLite®594 Fluorescent Dye
Excitation/Emission maxima wavelengths588 nm / 604 nm
Forme Liquide
Méthode de purification Purification par protéine A
Tampon de stockage PBS with 0.09% sodium azide and 0.5% BSA
Conditions de stockageStore at 2-8°C. Avoid exposure to light. Stable for one year after shipment.

Informations générales

BCMA (B cell maturation antigen), also known as TNFRSF17, is 20.2-kDa type III transmembrane glycoprotein and is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes and plasma cells, which may be important for B cell development and autoimmune response (PMID: 32943087; 9846698). BCMA has two agonist ligands: a proliferation-inducing ligand (APRIL) and BAFF. When BCMA binds to APRIL, it transmits signals of cell survival and proliferation (PMID: 27127303); when BCMA binds to BAFF, it mediates the activation of NF-kappaB and MAPK8/JNK (PMID: 36140254). It has been found that the overexpression and activation of BCMA are associated with multiple myeloma (MM) in preclinical models and humans, supporting its potential utility as a therapeutic target for MM (PMID: 32055000; 32943087).

Protocole

Product Specific Protocols
FC protocol for CL594 BCMA/TNFRSF17 antibody CL594-98215Download protocol
Standard Protocols
Click here to view our Standard Protocols
{{ptg:RelatedPrimaryAntibodies}}